The eradication of HCV.

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) infection impacts approximately 3% of the global population, potentially leading to severe liver conditions like cirrhosis and hepatocellular carcinoma.
• Despite challenges, HCV is a curable infection with significant advancements in diagnostics and therapeutics since the virus's discovery.

Purpose of the Study:

• To highlight the impact of direct-acting antiviral agents (DAAs) on Hepatitis C virus (HCV) treatment outcomes.
• To outline the necessary steps towards global HCV eradication, including diagnosis, treatment, and prevention.

Main Methods:

• Review of recent advancements in Hepatitis C virus (HCV) diagnostics and therapeutics.
• Analysis of the efficacy of direct-acting antiviral agents (DAAs) across different HCV genotypes and patient populations.
• Discussion of strategies for HCV control and eradication.

Main Results:

• Direct-acting antiviral agents (DAAs) offer short, well-tolerated, all-oral regimens with high sustained viral response (SVR) rates for all HCV genotypes.
• DAAs have expanded treatment options to patients previously considered difficult to treat or contraindicated due to advanced cirrhosis.
• Significant progress has been made, but challenges remain in patient identification, therapy access, and targeting high-risk groups.

Conclusions:

• Hepatitis C virus (HCV) is now a curable infection, with DAAs revolutionizing treatment outcomes.
• Achieving global HCV eradication necessitates a comprehensive strategy encompassing diagnosis, widespread treatment access, and targeted prevention of transmission.
• A concerted global effort is crucial to control morbidity/mortality, reduce incidence, and ultimately eliminate HCV worldwide.